Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 71.02% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.89% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.99% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -38.56% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 37.44% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 62.15% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.44% |
| Mar 31, 2026 | 47.10% |
| Dec 31, 2025 | 36.40% |
| Sep 30, 2025 | 39.61% |
| Jun 30, 2025 | 37.95% |
| Mar 31, 2025 | 57.65% |
| Dec 31, 2024 | 31.31% |
| Sep 30, 2024 | 18.29% |
| Jun 30, 2024 | 55.34% |
| Mar 31, 2024 | 30.95% |
| Dec 31, 2023 | 17.28% |
| Sep 30, 2023 | 37.21% |
| Jun 30, 2023 | -15.48% |
| Mar 31, 2023 | 1.51% |
| Dec 31, 2022 | 9.09% |
| Sep 30, 2022 | -24.86% |
| Jun 30, 2022 | -8.12% |
| Mar 31, 2022 | -9.73% |
| Dec 31, 2021 | -6.92% |
| Sep 30, 2021 | 5.88% |